Haliksol syrup 30mg / 100ml 10ml vial

Description

Composition
Active substance:
10 ml of syrup contains 30 mg of ambroxol hydrochloride.
Excipients:
Sorbitol, povidone (K-90), citric acid monohydrate, sodium cyclamate, flavoring 22754 strawberry, banana flavoring 270,650, sodium benzoate, sodium citrate and purified water.
Description:
A colorless or pale-yellow, transparent liquid without precipitate having a characteristic odor.
Product form:
100 ml of syrup in brown glass bottle with a white aluminum lid with tamper-evident. 1 vial together with instructions for use and packaged in measured glass cardboard box.
Contraindications
Hypersensitivity to ambroxol or Bromhexine.
Ulcerative lesions of the gastrointestinal tract.
Pregnancy (I term)
Precautions: severe renal insufficiency.
Dosage
3 mg / ml
Indications
Acute and chronic respiratory diseases, accompanied by the formation of viscous mucus: bronchitis, bronchial asthma, chronic obstructive pulmonary disease, pneumonia, bronchiectasis.
Inflammatory diseases of upper respiratory tract (sinusitis, otitis) at which the necessary liquefaction of mucus.
Interaction with other drugs
Antitussive drugs (including codeine) may impede sputum, ambroxol thinned.
Haliksol promotes penetration into bronchial secretions of certain antibiotics (amoxycillin, cefuroxime, erythromycin, doxycycline, etc.).
Overdose
Symptoms include nausea, vomiting, diarrhea, dyspepsia.
Treatment: Induce vomiting, and then assign a drink (milk or tea) intake of fat-containing products. Gastric lavage recommended for 1-2 hours after ingestion. It is necessary to constantly monitor the function of the cardiovascular system.
pharmachologic effect
Pharmacological group:
Expectorant (mucolytic) tool.
Pharmacodynamics:
Ambroxol – active bromhexine metabolite, belongs to the group of the benzylamine mucolytic agents.
Liquefies mucus production by increasing and enhancing the activity of hydrolytic enzymes that break the connection between sputum mucopolysaccharides.
It improves the rheological properties of sputum, reducing its viscosity and adhesive properties, due to the stimulation of the serous gland cells of the bronchial mucosa and normalization of the ratio of serous and mucous sputum components. Increases mucociliary transport, increasing the motor activity of ciliated epithelium. Does not cause excessive secretion of education, reduces spastic bronchial hyperreactivity. It contributes to the development of surfactant.
The effect is 30 minutes after ingestion.
Pharmacokinetics:
Almost completely absorbed in the gastrointestinal tract. Approximately 80% bound to plasma proteins. Treated active metabolism “first pass” hepatic. Bioavailability after oral administration is about 60%. Time to maximum concentration – 2 hr.
Approximately 90% of the dose excreted in the urine in the form of a glucuronide conjugate of ambroxol or oxidized products of its metabolism. The half-life of about 7 hours increases with severe renal failure, is not changed with abnormal liver function.
It crosses the placental barrier. Its concentration in the body of the fetus is 2-4 times higher than in the mother. It is found in breast milk, and cerebrospinal fluid.
Pregnancy and breast-feeding
The drug is contraindicated to receive in the I trimester of pregnancy; the drug is released in breast milk, so while taking the drug during lactation should decide the issue of termination of breastfeeding.
Conditions of supply of pharmacies
Without recipe.
side effects
Haliksol usually well tolerated. Rarely may experience the following side effects: fatigue, headache, diarrhea, constipation, dry mouth and airways, rhinorrhea, dysuria, gastralgia, nausea, vomiting, rash, urticaria. Very rare reports of severe acute anaphylactic reactions, but their causal relationship to ambroxol reception is not set.
special instructions
Should not be administered with antitussive drugs – difficulty sputum. Use of the drug in patients with impaired motor function of bronchi or copious sputum low viscosity requires caution because of the danger of stagnation of bronchial secretions.
Syrup contains nonspecific sweeteners, sorbitol, and sodium cyclamate, therefore diabetics can use this drug, but the content of sorbitol (1.2 g per 5 ml of syrup) must be taken into account by patients suffering from diabetes.
Product does not contain alcohol.
Storage conditions
Store at a temperature of 15-25 ° C, out of reach of children.
Dosing and Administration
Inside, after eating, and drinking plenty of fluids. Syrup can be taken with measuring cap, which is provided with the drug. Abundant fluid intake promotes liquefaction of mucus in the treatment Haliksolom.
Adults and children over 12 years: The usual daily dose for the first 2-3 days of treatment: 10 ml of syrup 3 times a day, and in the following days – 10 ml syrup 2 times a day, or 5 ml of syrup 3 times a day. In severe cases, the dose is not reduced during the course of treatment.
Children aged 2: 2.5 ml of syrup 2 times per day. 2-5 years: 2.5 ml syrup 3 times a day. 5-12 years: 5 ml of syrup 2-3 times a day.
In severe renal insufficiency should be given reduced doses or increase the intervals between doses of the drug.
When receiving Haliksola more than 4-5 days it is recommended to consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist